Literature DB >> 23139214

Cell surface receptor FPR2 promotes antitumor host defense by limiting M2 polarization of macrophages.

Ying Liu1, Keqiang Chen, Chunyan Wang, Wanghua Gong, Teizo Yoshimura, Mingyong Liu, Ji Ming Wang.   

Abstract

FPR2 (Fpr2 in mouse) is a G-protein-coupled receptor interacting with bacterial and host-derived chemotactic agonists. Fpr2 supports innate and adaptive immune responses as illustrated by the reduction in severity of allergic airway inflammation in Fpr2-KO mice, due to impaired trafficking of antigen-presenting dendritic cells (DC). The aim of this study is to examine the role of Fpr2 in host antitumor responses. We found that Fpr2-KO mice bearing subcutaneously implanted Lewis lung carcinoma (LLC) cells exhibited significantly shortened survival than normal mice due to more rapidly growing tumors. In contrast, in Fpr2-transgenic mice overexpressing Fpr2, subcutaneously implanted LLC tumors grew more slowly than those in wild-type (WT) littermates. Investigation of tumor tissues revealed an increased number of macrophages associated with tumors grown in Fpr2-KO mice. Macrophages derived from Fpr2-KO mice showed a more potent chemotactic response to LLC-derived supernatant (LLC Sup), which could be neutralized by an anti-CCL2 antibody. The increased chemotaxis of Fpr2-KO mouse macrophages in response to LLC Sup was due to their higher level expression of CCR4, a chemokine receptor that also recognizes the ligand CCL2. Furthermore, macrophages from Fpr2-KO mice acquired an M2 phenotype after stimulation with LLC Sup. These results suggest that Fpr2 plays an important role in host defense against implanted LLC by sustaining macrophages in an M1 phenotype with more potent antitumor activities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23139214      PMCID: PMC3549056          DOI: 10.1158/0008-5472.CAN-12-2290

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  Formyl-peptide receptors revisited.

Authors:  Yingying Le; Philip M Murphy; Ji Ming Wang
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

2.  RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4.

Authors:  Eliane Shizuka Nakamura; Keiichi Koizumi; Mitsuo Kobayashi; Yurika Saitoh; Yoshihisa Arita; Takashi Nakayama; Hiroaki Sakurai; Osamu Yoshie; Ikuo Saiki
Journal:  Clin Exp Metastasis       Date:  2006-07-05       Impact factor: 5.150

3.  CD16+ monocyte-derived macrophages activate resting T cells for HIV infection by producing CCR3 and CCR4 ligands.

Authors:  Petronela Ancuta; Patrick Autissier; Alysse Wurcel; Tauheed Zaman; David Stone; Dana Gabuzda
Journal:  J Immunol       Date:  2006-05-15       Impact factor: 5.422

4.  The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells.

Authors:  Seth B Coffelt; Frank C Marini; Keri Watson; Kevin J Zwezdaryk; Jennifer L Dembinski; Heather L LaMarca; Suzanne L Tomchuck; Kerstin Honer zu Bentrup; Elizabeth S Danka; Sarah L Henkle; Aline B Scandurro
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

Review 5.  Inflammatory cell infiltration of tumors: Jekyll or Hyde.

Authors:  James E Talmadge; Moses Donkor; Eric Scholar
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

6.  Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice.

Authors:  Boryana Konstantinova Popivanova; Feodora Ivanova Kostadinova; Kengo Furuichi; Mohamed M Shamekh; Toshikazu Kondo; Takashi Wada; Kensuke Egashira; Naofumi Mukaida
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

Review 7.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

Review 8.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

Review 9.  Exploring the full spectrum of macrophage activation.

Authors:  David M Mosser; Justin P Edwards
Journal:  Nat Rev Immunol       Date:  2008-12       Impact factor: 53.106

10.  Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis.

Authors:  Yurika Yogo; Seitaro Fujishima; Takashi Inoue; Fumitake Saito; Takayuki Shiomi; Kazuhiro Yamaguchi; Akitoshi Ishizaka
Journal:  Respir Res       Date:  2009-08-29
View more
  38 in total

Review 1.  New development in studies of formyl-peptide receptors: critical roles in host defense.

Authors:  Liangzhu Li; Keqiang Chen; Yi Xiang; Teizo Yoshimura; Shaobo Su; Jianwei Zhu; Xiu-wu Bian; Ji Ming Wang
Journal:  J Leukoc Biol       Date:  2015-12-23       Impact factor: 4.962

Review 2.  The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.

Authors:  Mithun Sharma; Shasikala Mitnala; Ravi K Vishnubhotla; Rathin Mukherjee; Duvvur N Reddy; Padaki N Rao
Journal:  J Clin Exp Hepatol       Date:  2015-02-16

Review 3.  Molecular biology for formyl peptide receptors in human diseases.

Authors:  Yongsheng Li; Duyun Ye
Journal:  J Mol Med (Berl)       Date:  2013-02-13       Impact factor: 4.599

4.  Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs.

Authors:  Xuemei Jia; Fang Yu; Junfeng Wang; Stephen Iwanowycz; Fatma Saaoud; Yuzhen Wang; Jun Hu; Qian Wang; Daping Fan
Journal:  Breast Cancer Res Treat       Date:  2014-10-14       Impact factor: 4.872

5.  The resolvin D1 analogue controls maturation of dendritic cells and suppresses alloimmunity in corneal transplantation.

Authors:  Jing Hua; Yiping Jin; Yihe Chen; Takenori Inomata; HyunSoo Lee; Sunil K Chauhan; Nicos A Petasis; Charles N Serhan; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-21       Impact factor: 4.799

6.  Formyl peptide receptor suppresses melanoma development and promotes NK cell migration.

Authors:  Jian Liu; Jun Li; Xiang Zeng; Zhiguo Rao; Jianfei Gao; Bicheng Zhang; Yong Zhao; Bo Yang; Zhigang Wang; Lifang Yu; Weixing Wang
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

7.  CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model.

Authors:  Steve Oghumu; Sanjay Varikuti; Cesar Terrazas; Dmitri Kotov; Mohd W Nasser; Catherine A Powell; Ramesh K Ganju; Abhay R Satoskar
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

8.  Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer.

Authors:  Jillian L Perry; Shaomin Tian; Nisitha Sengottuvel; Emily B Harrison; Balachandra K Gorentla; Chintan H Kapadia; Ning Cheng; J Christopher Luft; Jenny P-Y Ting; Joseph M DeSimone; Chad V Pecot
Journal:  ACS Nano       Date:  2020-06-02       Impact factor: 15.881

9.  The formylpeptide receptor 2 (Fpr2) and its endogenous ligand cathelin-related antimicrobial peptide (CRAMP) promote dendritic cell maturation.

Authors:  Keqiang Chen; Yi Xiang; Jiaqiang Huang; Wanghua Gong; Teizo Yoshimura; Qun Jiang; Lino Tessarollo; Yingying Le; Ji Ming Wang
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

Review 10.  The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally?

Authors:  Teizo Yoshimura
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.